• By ICR Secretariat
  • Posted Thursday, July 21, 2022

Royalty Pharma buys rights to top-selling GSK drug in pair of deals

https://www.biopharmadive.com/news/royalty-pharma-trelegy-theravance-innoviva-deal/627285/

  • Royalty Pharma, which calls itself the largest buyer of biopharmaceutical royalties, said Wednesday it’s undertaking a two-pronged transaction to acquire royalty rights to GSK’s blockbuster respiratory drug Trelegy Ellipta.